

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-----------------|----------------------|------------------------|------------------|
| 10/728,420 | 12/05/2003 | Susan L. Woulfe | 43407-P006US | 8619 |
| 75 | 7590 08/04/2006 | | EXAMINER | |
| Carol M. Nielsen Winstead Sechrest & Minick P.C. P.O. Box 50784 Dallas, TX 75201 | | | EMCH, GREGORY S | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 1649 | |
| | | | DATE MAILED: 08/04/200 | 6 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) |
|---|--|--|
| | 10/728,420 | WOULFE ET AL. |
| Office Action Summary | Examiner | Art Unit |
| | Gregory S. Emch | 1649 |
| The MAILING DATE of this communication of the second se | appears on the cover sheet w | ith the correspondence address |
| A SHORTENED STATUTORY PERIOD FOR REI WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b). | B DATE OF THIS COMMUNI R 1.136(a). In no event, however, may a riod will apply and will expire SIX (6) MOI atute, cause the application to become A | CATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133). |
| Status | | |
| 1) Responsive to communication(s) filed on 05 2a) This action is FINAL . 2b) X 3) Since this application is in condition for allow closed in accordance with the practice under | his action is non-final. wance except for formal mat | |
| Disposition of Claims | | |
| 4) ☐ Claim(s) <u>1-87</u> is/are pending in the applicating 4a) Of the above claim(s) is/are without 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) <u>1-87</u> are subject to restriction and/ | drawn from consideration. | |
| Application Papers | | |
| 9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the constant of t | accepted or b) objected to the drawing(s) be held in abeya rection is required if the drawing | nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d). |
| Priority under 35 U.S.C. § 119 | | |
| 12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the papplication from the International Bur * See the attached detailed Office action for a | ents have been received. ents have been received in A priority documents have beer reau (PCT Rule 17.2(a)). | Application No n received in this National Stage |
| | | |
| Attachment(s) | | |
| 1) Notice of References Cited (PTO-892) | · — | Summary (PTO-413) |
| Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date | —————————————————————————————————————— | (s)/Mail Date Informal Patent Application (PTO-152) |

Paper No(s)/Mail Date _

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-33 and 49-87 are drawn to a method of treating an inflammatory disease or disorder comprising administering an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug, classified in class 424, subclass 130.1, for example.
- II. Claims 34-48 are drawn to a composition for the treatment, prevention, or inhibition of inflammation comprising an anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 and at least one disease modifying anti-rheumatic drug, classified in class 424, subclass 145.1, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the products of invention I can be used in *in vivo* imaging techniques, for example.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1649

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicants are advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should Applicants traverse on the ground that the inventions or species are not patentably distinct, applicants should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/728,420

Art Unit: 1649

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicants are advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the

Application/Control Number: 10/728,420 Page 5

Art Unit: 1649

product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Examiner Gregory S. Emch, Art Unit 1649.

Application/Control Number: 10/728,420 Page 6

Art Unit: 1649

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gregory S. Emch whose telephone number is (571) 272-8149. The examiner can normally be reached on Monday through Friday from 9AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres can be reached at (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gregory S. Ernch, Ph.D.

Patent Examiner Art Unit 1649 01 August 2006

JANET L. ANDRES
SUPERVISORY PATENT EXAMINER